Trial Profile

A Phase Ib Trial With Dose Expansion Evaluating CPX-351 Plus Gemtuzumab Ozogamicin for Relapsed Acute Myelogenous Leukemia

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 10 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cytarabine/daunorubicin (Primary) ; Gemtuzumab ozogamicin (Primary)
Indications Acute myeloid leukaemia
Focus Adverse reactions

Most Recent Events

01 Apr 2025 Results evaluating safety and efficacy of gemtuzumab ozogamicin when given together with CPX-351 published in the Leukemia and Lymphoma.
17 Nov 2023 Status changed from active, no longer recruiting to discontinued.
04 Aug 2023 Planned End Date changed from 1 Jul 2024 to 1 Jul 2025.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com